US AF Prevalence
6–7 M
Approximately 6–7 million Americans live with AF — the most common sustained cardiac arrhythmia in the world. Projected to reach 12 million by 2030 as the population ages.[1]
What Is It
Definition, mechanism, and the clinical reality of atrial fibrillation at end of life. What the hospice team needs to understand on day one.
Lifetime Risk
~25%
Roughly 1 in 4 adults over 40 will develop AF in their lifetime — a risk that is higher than most clinicians and patients realize, and rising with obesity and aging populations.[2]
Stroke Risk Multiplier
2–5×
AF increases stroke risk 2–5 fold compared to sinus rhythm. Cardioembolic strokes from AF are typically larger, more disabling, and carry higher mortality than atherosclerotic strokes.[3]
Permanent AF in End-Stage Heart Disease
40–60%
An estimated 40–60% of patients with end-stage CHF, cardiomyopathy, or valvular disease have permanent or persistent AF. AF is rarely the primary hospice diagnosis but is nearly universal as a comorbidity in the cardiac hospice population.[4]
Atrial fibrillation is the chaotic, disorganized electrical activation of the atria — the two upper chambers of the heart. Instead of the normal coordinated contraction that pushes blood efficiently into the ventricles, the atria fibrillate at 350–600 impulses per minute, producing an irregularly irregular ventricular response and eliminating the organized atrial contraction ("atrial kick") that normally contributes 20–30% of ventricular filling. In a healthy heart, losing the atrial kick is compensated. In a diseased heart — the one you will see in hospice — it is the difference between compensated and decompensated heart failure.[1]
In end-stage cardiac disease, AF is almost never the primary diagnosis and almost always a significant complicating factor. It worsens CHF by reducing filling efficiency and driving tachycardia-induced cardiomyopathy. It creates embolic stroke risk that requires anticoagulation — with its attendant bleeding risk — throughout the disease trajectory. It requires rate or rhythm control medications that add to pill burden and cause their own complications (bradycardia, hypotension, digoxin toxicity). And in the end-stage patient who is frail, at high bleeding risk, and approaching death, the anticoagulation that has been serving the patient for years may become the medication most needing reassessment.[5]
The hospice clinician inheriting an AF patient must make two decisions explicitly that have almost never been addressed: Is anticoagulation still serving this patient given their current bleeding risk, life expectancy, and goals? And: Is the current rate control target still appropriate or is lenient rate control sufficient to reduce medication burden? These two questions shape the medication list more than any other assessment at enrollment.[6]
🧭 Clinical framing
AF in hospice is a comorbidity management problem, not a primary disease management problem. The underlying structural heart disease — CHF, cardiomyopathy, valvular disease — drives the trajectory. AF makes that trajectory harder by reducing cardiac efficiency, increasing medication burden, creating stroke and bleeding risk, and generating symptoms (palpitations, dyspnea, fatigue) that overlap with and amplify the underlying disease. Your job is not to cure the AF. Your job is to minimize its contribution to suffering while the primary disease runs its course.
"Nobody gets admitted to hospice for AF. They get admitted for the CHF, the cardiomyopathy, the valvular disease — and the AF rides along making everything worse. The first thing I do at the AF hospice visit is check the heart rate and look at the med list. If the rate is running 110 and they're still on warfarin with an INR nobody's checked in three weeks, I know exactly what my visit is about."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, classification, and what to look for in hospice records. Most patients arrive with an established AF diagnosis — this section helps you read it and identify what still needs attention.
Diagnostic Workup
- 12-lead ECG (gold standard): Absence of discrete P waves replaced by irregularly irregular fibrillatory baseline; irregularly irregular R-R intervals; ventricular rate depends on AV node conduction and rate-control medications. The ventricular rate at the hospice visit tells you whether rate control is adequate.[7]
- Ambulatory monitoring: Holter 24–48h; event recorder 2–4 weeks; implantable loop recorder for paroxysmal AF. In hospice, continuous monitoring is rarely indicated unless arrhythmia pattern is uncertain and management decisions depend on it.
- Echocardiogram (essential): Left atrial size (LA >4.5 cm = increased recurrence, poor rhythm control candidacy), LV ejection fraction (tachycardia-induced cardiomyopathy if rate-related), valvular disease (mitral stenosis = warfarin-only indication), intracardiac thrombus assessment.[8]
- TSH: Hyperthyroidism causes AF; amiodarone causes thyroid dysfunction in 15–30% of patients. Check at enrollment.
- Electrolytes: Hypokalemia and hypomagnesemia precipitate AF and make rate control harder. Correct before escalating medications.
What to Look for in Hospice Records
- AF classification: Paroxysmal (<7 days self-terminating), persistent (≥7 days), long-standing persistent (≥12 months), permanent (rhythm control no longer pursued). Permanent AF is the classification most relevant to hospice.[7]
- CHA₂DS₂-VASc score: CHF 1pt, Hypertension 1pt, Age≥75 2pts, Diabetes 1pt, Stroke/TIA 2pts, Vascular disease 1pt, Age 65–74 1pt, Sex (female) 1pt. Score drives anticoagulation decision.
- HAS-BLED score: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly >65, Drugs/alcohol. Score ≥3 = high bleeding risk.[9]
- Prior interventions: Cardioversions (how many, last one), ablation procedures (PVI, AV node ablation), pacemaker or ICD in place, prior bleeding events on anticoagulation.
- Current anticoagulant: Warfarin (last INR, TTR), DOAC type and dose, or none. This is the single most important medication to assess at enrollment.
💡 For families
💡 Para las familias
Your loved one has a heart rhythm condition called atrial fibrillation — the heart beats irregularly instead of in a steady rhythm. This has been diagnosed and is being managed with medications. At this stage, the hospice team's focus is on making sure those medications are working well, that side effects are minimized, and that your loved one is as comfortable as possible. Most of the diagnostic testing is already complete.
Su ser querido tiene una condición del ritmo cardíaco llamada fibrilación auricular — el corazón late de manera irregular. Esto ya ha sido diagnosticado y se está manejando con medicamentos. El equipo de hospicio se enfoca en asegurar que esos medicamentos funcionen bien y que su ser querido esté lo más cómodo posible.
Causes & Risk Factors
Modifiable and non-modifiable risk factors. Relevant for family conversations and answering "why did this happen?"
Modifiable Risk Factors
- Hypertension: The most common cause of AF in the US — chronic pressure overload causes left atrial dilation and fibrosis creating the substrate for AF. Present in 60–80% of AF patients.[10]
- Obesity: Major independent risk factor — adipose infiltration of atria and elevated filling pressures from obesity-related diastolic dysfunction. Weight loss reduces AF burden in earlier stages.
- Obstructive sleep apnea: Significant independent risk — intermittent hypoxia and autonomic dysregulation create AF substrate. CPAP reduces AF recurrence.
- Alcohol use: Holiday heart syndrome — acute AF triggered by binge drinking. Chronic heavy use causes atrial remodeling and structural cardiomyopathy. Even moderate alcohol increases AF risk in susceptible individuals.[11]
- Hyperthyroidism: Thyroid hormone directly increases atrial automaticity. TSH should be checked in all new-onset AF. Amiodarone causes hypothyroidism in 15–30% and hyperthyroidism in 2–10% of patients.
Hereditary & Non-Modifiable
- Age: AF prevalence doubles with each decade after age 50. Atrial fibrosis and conduction slowing are normal aging processes. Prevalence 9–14% in patients over 80.[1]
- Heart failure and cardiomyopathy: AF and CHF are bidirectional — CHF causes AF through LA dilation; AF worsens CHF through tachycardia-induced cardiomyopathy and loss of atrial kick. They coexist in 40–50% of severe CHF.[4]
- Valvular heart disease: Mitral stenosis — the classic cause of rheumatic AF. Mitral regurgitation, aortic stenosis, and mitral valve prolapse all increase LA pressure and AF risk.
- Coronary artery disease / prior MI: Ischemic injury to atrial conduction system, post-MI inflammation.
- Cardiac surgery: Postoperative AF is common, especially after CABG. Often resolves but contributes to the chronic AF population.
- Familial AF: Genetic variants in ion channels (KCNQ1, KCNA5, SCN5A) confer independent risk; family history of AF increases personal risk 40%.[12]
❤️ For families: "Why did this happen?"
Atrial fibrillation is extremely common — it affects millions of people and becomes more likely as we age and as the heart faces other challenges like high blood pressure, heart failure, or valve problems. It was not caused by something your loved one did wrong. It is a consequence of the heart's electrical system wearing down over time, often in combination with other heart conditions. There is no single cause — and there is nothing you or they could have done differently to prevent it.
⚕ Clinician note: Comorbidity overlap
In the hospice AF population, the risk factors are the comorbidities that brought the patient to hospice. Almost every AF patient on your caseload has CHF, hypertension, valvular disease, or cardiomyopathy — the AF is the electrical manifestation of the structural disease that is the primary diagnosis. Understanding the underlying structural cause tells you whether rate control alone is sufficient (most cases) or whether rhythm restoration would meaningfully change function (rare at end of life, but occasionally relevant in acute-onset AF causing new decompensation).
Treatments & Procedures
What AF-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
AF management divides into three pillars: rate control, rhythm control, and anticoagulation. Most hospice patients with permanent AF are managed with rate control and anticoagulation alone. Understanding what the patient has already been through — how many cardioversions, whether ablation was attempted, which antiarrhythmics failed — helps you understand why they are where they are and what realistic expectations look like going forward.[13]
Rate Control Strategies
- Beta-blockers (metoprolol, carvedilol): First-line rate control. Reduce HR via AV node slowing. Negative inotropy must be considered in HFrEF. Most patients tolerate well.[14]
- Rate-limiting CCBs (diltiazem, verapamil): Effective AV node blockers. Avoid in HFrEF — negative inotropy worsens reduced EF. Appropriate in HFpEF.
- Digoxin: Vagally-mediated AV node slowing. Narrow therapeutic window (0.5–0.9 ng/mL). Accumulates in renal failure. Useful in HFrEF with AF when beta-blocker alone insufficient.[15]
- Amiodarone (for rate control): When other agents insufficient. Serious long-term toxicities: pulmonary, thyroid, hepatic, corneal, neuropathic. Half-life 40–55 days. Reassess monitoring burden at hospice enrollment.[16]
- AV node ablation + pacemaker: Definitive rate control for refractory cases. Eliminates need for rate-control medications. The patient with a pacemaker post-AV node ablation has excellent rate control and no rate-control medication burden.
Rhythm Control & Anticoagulation
- Electrical cardioversion: DC cardioversion — most effective acute rhythm conversion. TEE to exclude LAA thrombus if not anticoagulated ≥3 weeks. In hospice, cardioversion for acute-onset AF causing decompensation is a comfort-compatible discussion.[17]
- Catheter ablation (PVI): Pulmonary vein isolation. Success rates 60–80% for paroxysmal AF, lower for persistent. CABANA and CASTLE-AF trials showed benefit in selected patients with CHF. Most hospice patients have already failed or are not candidates.[18]
- Antiarrhythmic drugs: Flecainide, propafenone (structurally normal hearts only), sotalol, dofetilide, dronedarone, amiodarone. At end of life, reassess whether continued antiarrhythmic therapy and its monitoring burden is consistent with comfort goals.
- DOACs: Apixaban (ARISTOTLE), rivaroxaban (ROCKET-AF), dabigatran (RE-LY), edoxaban (ENGAGE-AF). Superior to warfarin for non-valvular AF. Apixaban has lowest bleeding rates.[19]
- Warfarin: Required for mechanical valves and mitral stenosis AF. INR monitoring burden significant. Transition to DOAC should be considered at enrollment when appropriate.
When Therapy Makes Sense
Evidence-based criteria for continuing AF-directed therapy in the hospice setting. This is not about giving up or holding on — it's about reading the data correctly.
AF-directed therapy in hospice is justified when it reduces symptom burden or prevents a complication that would significantly worsen quality of remaining life. The following criteria identify patients for whom continued active AF management serves comfort goals.[14]
- 01Rate control to ≤80–110 bpm in permanent AF with structural heart disease: Inadequate rate control causes tachycardia-induced cardiomyopathy, worsens dyspnea, and reduces functional capacity. Optimizing rate control is a primary comfort intervention. If resting heart rate is >110 bpm and patient is symptomatic, medication optimization is warranted.[20]
- 02Tachycardia-induced cardiomyopathy identification and aggressive rate control: If a patient's reduced EF is primarily driven by tachycardia rather than structural disease, aggressive rate control (target <80 bpm) or AV node ablation may restore meaningful EF within 3–6 months. This is one of the few reversible causes of cardiomyopathy and deserves explicit identification at hospice enrollment.[21]
- 03Anticoagulation continuation in patients with CHA₂DS₂-VASc ≥2 and acceptable bleeding risk with life expectancy >3 months: In patients with meaningful life expectancy and predominantly embolic stroke risk without prohibitive bleeding risk, DOAC continuation reduces the risk of disabling cardioembolic stroke. Apixaban is preferred for its superior safety profile.[19]
- 04Cardioversion for acute-onset AF causing hemodynamic decompensation: Even in comfort-focused patients, restoring sinus rhythm in acute AF-triggered decompensation is a legitimate comfort intervention if the patient was recently in sinus rhythm and sinus rhythm provides meaningfully better function.[17]
- 05Patient goals explicitly include stroke prevention: A well-informed patient who understands both the stroke and bleeding risks and chooses to continue anticoagulation has exercised valid autonomy. Document the informed discussion, the CHA₂DS₂-VASc and HAS-BLED scores, and the patient's stated goals.
When It Doesn't
Knowing when AF-directed treatment stops helping is not clinical failure. It is the most important clinical skill in managing AF at end of life.
Anticoagulation deprescribing at end of life is the most frequently needed and least frequently completed medication decision in the AF hospice population. The cardiologist started it. No one has discussed stopping it. The hospice team inherits the responsibility.[22]
- 01Estimated survival <1–3 months with purely comfort-focused goals: The patient who will die within weeks from cancer, CHF, or respiratory failure receives no meaningful stroke protection benefit from anticoagulation that they would not live long enough to receive, while bearing all the immediate bleeding burden. Anticoagulation discontinuation in the actively dying patient is standard palliative practice.[22]
- 02HAS-BLED ≥3 with prior serious bleeding event: Prior intracranial hemorrhage is an absolute contraindication to anticoagulation regardless of CHA₂DS₂-VASc score. Active GI bleeding, recurrent falls causing hemorrhagic trauma — in these cases bleeding risk clearly outweighs embolic risk.[9]
- 03Patient goals explicitly declining anticoagulation: The patient who understands the stroke risk and declines anticoagulation due to pill burden, monitoring burden, or quality-of-life preference has exercised valid autonomy. Document explicitly: CHA₂DS₂-VASc score, HAS-BLED score, risk explained, patient decision, and reasoning.
- 04Severe renal failure with GFR <15: All DOACs require GFR ≥15–25 for safety. Warfarin is the only option in severe renal failure but INR instability in end-stage disease makes it burdensome. The benefit-burden ratio shifts dramatically.[23]
- 05Rhythm control when permanent AF is established: Multiple failed cardioversions and ablations. Amiodarone toxicity monitoring (LFTs, TFTs, CXR, ophthalmology) exceeding clinical benefit. Antiarrhythmic drug side effects causing more burden than benefit. Stopping amiodarone after prolonged use must be managed carefully — half-life 40–55 days.[16]
- 06Rate control medication causing more harm than good: Hypotension from beta-blockers in advanced CHF, symptomatic bradycardia, digoxin toxicity. If rate control medication is causing falls, syncope, or debilitating fatigue, dose reduction or discontinuation — even if heart rate rises — may improve overall comfort.
📋 Clinician note: The anticoagulation conversation
Stopping anticoagulation is the most emotionally loaded medication deprescribing decision in AF hospice. The patient and family have been told for years that the blood thinner prevents stroke. Stopping it feels like abandonment to many families. Frame it explicitly: "Stopping the blood thinner is not stopping caring for you. It is choosing to remove a bleeding risk now that your situation has changed. The blood thinner has done its job protecting you — but as things change, the risks of continuing it may now outweigh the benefits." Document the conversation, the clinical reasoning, the scores, and the patient/family response.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Lenient vs Strict Rate Control
Grade ALenient target: ≤110 bpm at rest vs Strict target: ≤80 bpm
The RACE II trial demonstrated that lenient rate control (≤110 bpm) is non-inferior to strict rate control (≤80 bpm) for cardiovascular outcomes in permanent AF patients with preserved EF. Lenient rate control requires fewer medications and lower doses. In elderly frail patients with permanent AF and no EF reduction, targeting ≤110 bpm allows lower medication burden with equivalent outcomes. In patients with reduced EF or tachycardia-induced cardiomyopathy, strict control ≤80 bpm remains important. Individualize by symptoms and EF. This is a meaningful medication burden reduction opportunity in many AF hospice patients.[20]
DOAC over Warfarin Transition
Grade ASwitch warfarin → apixaban 5 mg BID (or 2.5 mg BID if criteria met)
DOACs are superior to warfarin for both stroke prevention and intracranial hemorrhage reduction in non-valvular AF. ARISTOTLE trial: apixaban reduced stroke, major bleeding, and mortality vs warfarin. Apixaban specifically has the lowest GI and intracranial bleeding rates across all DOAC trials. In a hospice patient still desiring anticoagulation, switching from warfarin to apixaban eliminates INR monitoring, reduces bleeding risk, and reduces caregiver burden. The transition conversation at enrollment is a high-impact quality-of-life intervention. Contraindication: mechanical valve or mitral stenosis — warfarin required.[19]
Tachycardia-Induced Cardiomyopathy ID
Grade BAggressive rate control to <80 bpm for 3–6 months; or AV node ablation + pacemaker
Tachycardia-induced cardiomyopathy is underrecognized and fully reversible. The patient with reduced EF and permanent rapid AF whose EF has never been measured after adequate rate control may have a substantially recoverable cardiomyopathy. If rate has been running 110–130 bpm and EF is reduced, aggressive rate control to <80 bpm or AV node ablation with pacemaker may restore EF and dramatically improve functional status. This is one of the highest-impact interventions in the cardiac hospice population — identifying it changes the prognosis from terminal to potentially meaningful recovery.[21]
Yoga & Mindfulness for AF Symptom Burden
Grade BGuided sessions 2–3x/week; adapted for functional status; chair-based or supine
Multiple RCTs demonstrate that yoga reduces AF burden, symptom severity, anxiety, and depression in AF patients. Mindfulness meditation reduces palpitation-related anxiety and catastrophizing. In the hospice AF patient, the benefit is primarily anxiolytic — reducing the hypervigilance about heart rhythm that amplifies symptom perception. Adapted yoga (chair-based, breathing exercises, guided relaxation) is safe and can be delivered by trained volunteers or via recorded sessions. Refer to integrative medicine or complementary therapy team at enrollment.[24]
AV Node Ablation + Permanent Pacemaker
Grade BSingle procedure; eliminates need for all rate-control medications
For patients with rate-refractory AF causing persistent symptoms despite maximal pharmacologic rate control, AV node ablation with pacemaker placement is a definitive solution. Eliminates all rate-control medications, provides regular paced rhythm, and improves symptoms and quality of life. Appropriate in hospice when: life expectancy is sufficient to benefit (months), rate control has failed pharmacologically, and the patient's symptoms are primarily rate-driven. This is not an aggressive intervention — it is a comfort intervention that eliminates medication burden. Discuss with cardiology at enrollment.[25]
Magnesium Repletion for AF Control
Grade CMagnesium glycinate 200–400 mg daily; IV MgSO4 2g for acute rate control
Hypomagnesemia is extremely common in CHF and AF patients on diuretics. Low magnesium directly triggers AF and makes rate control harder. Correcting documented deficiency reduces AF frequency and improves rate control medication efficacy. Check serum magnesium at enrollment — levels <1.8 mg/dL warrant supplementation. Oral magnesium glycinate is well-tolerated. IV magnesium is used acutely for rate control augmentation in the hospital setting. No significant warfarin or DOAC interaction at standard oral dose.[26]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to AF. Patients will use supplements — this section helps you have the right conversation.
"Anticoagulation is the defining drug safety issue in AF hospice and it governs every supplement recommendation. Before recommending any supplement in AF, ask three questions: does it affect warfarin INR? Does it interact with DOACs via CYP3A4 or P-glycoprotein? Does it have antiplatelet activity that compounds anticoagulation? If the answer to any of these is yes, you need to know before the patient takes it — not after the bleeding event."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Magnesium glycinate | Grade B | 200–400 mg daily | Corrects magnesium depletion from diuretics; reduces AF frequency; improves rate control medication efficacy; one of the most impactful supplements in the AF hospice population[26] | No significant warfarin or DOAC interaction at this dose. Mild laxative effect at higher doses. Check serum Mg at enrollment. |
| Coenzyme Q10 (Ubiquinol) | Grade C | 100–200 mg daily | Mitochondrial support in AF with coexisting heart failure; may improve myocardial energy metabolism and reduce oxidative stress[27] | Minor warfarin interaction — may mildly reduce INR; monitor if on warfarin. No DOAC interaction at standard dose. Generally well tolerated. |
| Melatonin | Grade C | 1–3 mg at bedtime | Sleep disruption from palpitations and AF-related anxiety; improves sleep onset without respiratory depression; safe adjunct to sleep hygiene | No antiplatelet or anticoagulant effect. Minimal DOAC or warfarin interaction. One of the safest supplements in this population. Avoid doses >5 mg. |
| Omega-3 fatty acids | Grade C | 1 g/day food-source level | Anti-inflammatory effect; mild cardiovascular benefit at food-equivalent doses[28] | At ≤1 g/day: no significant anticoagulant interaction. At ≥4 g/day (prescription): increased bleeding risk with warfarin and DOACs; avoid high-dose in anticoagulated patients. REDUCE-IT dose (4 g icosapent ethyl) is NOT recommended in AF hospice. |
| Hawthorn (Crataegus) | Grade C | 160–900 mg daily standardized extract | Mild positive inotropic effect; may improve functional capacity in mild-moderate CHF with AF; traditional use for heart palpitations | Potentiates digoxin — contraindicated in patients on digoxin. May enhance hypotensive effects of beta-blockers and CCBs. Monitor BP if used with rate control medications. |
| L-Theanine | Grade D | 200–400 mg daily | Anxiolytic without sedation; reduces palpitation-related anxiety; promotes alpha-wave relaxation | No known anticoagulant interaction. Safe with DOACs and warfarin. No cardiac contraindications. May potentiate antihypertensives mildly. |
🚫 Avoid in AF Patients
- St. John's Wort: Potent CYP3A4 and P-glycoprotein inducer — dramatically reduces apixaban, rivaroxaban, and edoxaban levels rendering DOACs ineffective for stroke prevention. Reduces warfarin efficacy via CYP2C9 induction. Absolute contraindication in any anticoagulated AF patient.[29]
- Ginkgo biloba: Antiplatelet activity compounds anticoagulation bleeding risk. Case reports of serious hemorrhage with warfarin. Avoid in all anticoagulated AF patients.
- Ginseng (Panax): Affects warfarin metabolism unpredictably — both increases and decreases in INR reported. CYP3A4 interaction affects DOACs. Stimulant properties may worsen palpitations and AF burden.
- Ephedra / Ma huang / Bitter orange: Sympathomimetic stimulants — directly trigger AF episodes and increase ventricular rate. Absolute contraindication in any AF patient.
- High-dose fish oil (≥4 g/day): STRENGTH trial associated high-dose omega-3 with increased AF incidence. At prescription doses, compounds anticoagulation bleeding risk. Keep to ≤1 g/day food-source equivalent.[28]
- Dong Quai: Contains coumarins — potentiates warfarin significantly. Avoid in all patients on warfarin or DOACs.
Timeline Guide
A guide, not a prediction. AF is almost always a comorbidity — the timeline reflects AF management overlaid on the underlying disease trajectory.
The AF trajectory is almost entirely governed by the underlying structural heart disease — CHF, cardiomyopathy, valvular disease. AF itself rarely determines the timeline but significantly complicates every phase. What changes across the timeline is the AF management approach: from rhythm control to rate control to comfort-focused medication optimization to medication discontinuation. The anticoagulation decision point shifts at each phase.[5]
YRS–
MOS
MOS
Paroxysmal / Persistent AF — Active Management
- Paroxysmal or persistent AF on rhythm and/or rate control — episodes come and go; periodic cardioversion or on antiarrhythmic drug; functional and managing episodes
- Anticoagulation ongoing based on CHA₂DS₂-VASc score; regular INR monitoring if on warfarin; DOAC if eligible
- This phase can last years with careful management; palliative care integration is never offered for AF alone
- The underlying structural disease (CHF, valvular disease, cardiomyopathy) determines the primary trajectory
- Advance care planning should begin here — particularly around anticoagulation decisions ("What would you want if you developed a serious bleed?") and rhythm control goals ("What does sinus rhythm mean to you functionally?")
MOS–
1 YR
1 YR
Transition to Permanent AF — Rate Control Era
- Multiple failed cardioversions; rhythm control no longer pursued; rate control the exclusive strategy
- Anticoagulation ongoing; AF contributing to functional limitation through loss of atrial kick and tachycardia symptoms
- Underlying structural disease progressing; medication list growing; polypharmacy accelerating
- Window to reassess antiarrhythmic drugs for deprescribing — amiodarone monitoring burden may no longer serve the patient
- Consider warfarin-to-DOAC transition if still on warfarin for non-valvular AF; evaluate tachycardia-induced cardiomyopathy
WKS–
MOS
MOS
End-Stage Cardiac Disease with Permanent AF — Hospice Phase
- Underlying disease (CHF Stage D, cardiomyopathy, valvular disease) now driving the trajectory; AF contributing to symptom burden
- Hospice enrollment appropriate for the underlying diagnosis; AF medication review at enrollment is a primary clinical task
- Explicit anticoagulation reassessment — calculate CHA₂DS₂-VASc and HAS-BLED, estimate life expectancy, discuss with patient/family
- Rate control optimization; digoxin level check; medication burden reduction; identify tachycardia-induced cardiomyopathy if present
- Comfort kit preparation with attention to AF-specific symptoms: palpitation anxiety (lorazepam), dyspnea (morphine), fluid overload (furosemide)
DAYS–
WKS
WKS
Pre-Active Dying — Medication Simplification
- Bed-bound; minimal oral intake; sleeping most of day; underlying cardiac disease in terminal phase
- Anticoagulation discontinuation if not already done — the actively dying patient does not benefit from stroke prevention
- Rate control medications reduced or stopped if causing hypotension; switch to comfort-only medications
- Digoxin discontinued — risk of toxicity with declining renal function and dehydration; no benefit in comfort phase
- Family teaching: irregular heartbeat may become more noticeable as other medications are stopped — this is expected and is not causing suffering
HRS–
DAYS
DAYS
Final Hours
- Cheyne-Stokes or agonal breathing; mottling of extremities; peripheral cyanosis; mandibular breathing
- AF-specific risk: rapid ventricular response may cause visible distress — morphine and midazolam for comfort; heart rate monitoring is no longer indicated
- All rate control and anticoagulation medications discontinued; only comfort medications administered
- Family education: the irregular pulse may be palpable — this is the AF and is not causing pain; auditory awareness may persist — speak words of comfort
- Emergency medications drawn and labeled: morphine 2–4 mg SQ, midazolam 2.5–5 mg SQ, glycopyrrolate 0.2 mg SQ
Medications to Anticipate
Symptom-targeted pharmacology for AF at end of life. What to have in the comfort kit, what to titrate first, and the two decisions that shape the medication list.
AF medication management in hospice requires two explicit decisions. First: anticoagulation — is it still serving the patient given their current bleeding risk, life expectancy, and goals? Document the decision. Second: rate control target — is strict rate control still warranted or is lenient rate control (≤110 bpm) acceptable? These two decisions shape the medication list more than any other assessment. Additionally, amiodarone requires ongoing monitoring often inconsistent with comfort goals — assess at enrollment.[14]
| Drug | Class / Target | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Metoprolol succinate | Beta-blocker / Rate control | 25–200 mg PO daily | First-line rate control. Reduce dose as BP falls. If hypotension develops, reduce or stop. Rate control goal ≤80–110 bpm depending on EF and symptoms.[14] |
| Carvedilol | Beta-blocker / Rate control (HFrEF) | 3.125–25 mg PO BID | Preferred in HFrEF for combined rate control and CHF benefit. Alpha-blocking activity: more hypotension risk. Reduce dose gradually at end of life. |
| Diltiazem | CCB / Rate control | 120–360 mg PO daily (extended release) | Alternative or adjunct rate control. ⚠ Avoid in HFrEF — negative inotropy worsens reduced EF. Appropriate in HFpEF. Avoid combining with beta-blocker at high doses — complete heart block risk.[30] |
| Digoxin | Cardiac glycoside / Rate control adjunct | 0.125 mg PO daily | Useful in HFrEF when beta-blocker alone insufficient. Target level 0.5–0.9 ng/mL. ⚠ Check level and creatinine at enrollment — accumulates in renal failure. Above 1.5 ng/mL: toxicity (nausea, anorexia, visual changes). Common reversible cause of nausea in elderly hospice patients.[15] Check digoxin level at enrollment and every 4–8 weeks. Toxicity is the most commonly missed treatable problem in AF hospice. |
| Apixaban | DOAC / Stroke prevention | 5 mg PO BID; 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5 | Preferred DOAC for non-valvular AF. Lowest intracranial hemorrhage rate. ARISTOTLE trial: superior to warfarin for stroke, bleeding, and mortality. Reassess at enrollment: is anticoagulation still serving this patient?[19] |
| Rivaroxaban | DOAC / Stroke prevention | 20 mg PO daily with food; 15 mg if CrCl 15–50 | Once-daily dosing may improve adherence. Higher GI bleeding rate than apixaban. Requires food for absorption. ROCKET-AF trial data.[31] |
| Warfarin | VKA / Stroke prevention | Dose per INR; target INR 2.0–3.0 | Required for mechanical valves and mitral stenosis AF. INR monitoring burden significant. TTR <65% = poor control, consider transition to DOAC if eligible. At enrollment, assess INR stability and monitoring feasibility.[32] |
| Furosemide | Loop diuretic / Fluid overload | 20–80 mg PO daily; titrate to symptoms | AF with CHF: fluid overload worsens dyspnea and AF rate. Diuresis is a primary comfort intervention. Monitor K+ and Mg2+ — hypokalemia and hypomagnesemia worsen AF. Replace electrolytes proactively. |
| Morphine | Opioid / Dyspnea + Pain | 2.5–5 mg PO/SQ q4h PRN | First-line for dyspnea in AF with CHF. Systemic route only. Reduces respiratory distress and anxiety. Titrate to comfort.[33] |
| Lorazepam | Benzodiazepine / Palpitation anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Adjunctive for palpitation-related anxiety. The AF patient with hypervigilance about heart rhythm benefits from PRN anxiolysis. Limited evidence for dyspnea alone. |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN | Terminal agitation and catastrophic symptom management. Have in comfort kit drawn and labeled. For refractory distress in final hours. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Standard comfort kit medication. |
🌿 Symptom Management Decision Tree
Evidence-based · AF-adapted · Hospice-specificSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for AF Hospice
Rapid ventricular response crisis: Morphine 2–4 mg SQ + Lorazepam 0.5–1 mg SQ for acute dyspnea and distress from uncontrolled rate. Palpitation panic: Lorazepam 0.5 mg SQ/PO for acute anxiety from palpitation awareness. Acute CHF exacerbation: Furosemide 40 mg IV/SQ PRN for acute fluid overload causing respiratory distress. Terminal agitation: Midazolam 2.5–5 mg SQ drawn and labeled. Terminal secretions: Glycopyrrolate 0.2 mg SQ. Bleeding event (if still anticoagulated): Family education on compression, positioning, when to call; DOAC reversal agents (andexanet alfa for apixaban, idarucizumab for dabigatran) are hospital-only — determine in advance whether ER transport for major bleeding is consistent with patient goals.
Clinician Pointers
High-yield clinical pearls for the hospice team managing AF. The things not in the textbook — learned at the bedside over years of AF-specific clinical experience.
1
Anticoagulation is the most important medication to reassess at AF hospice enrollment
The cardiologist started it and no one has discussed stopping it. At enrollment: calculate CHA₂DS₂-VASc and HAS-BLED, estimate life expectancy, ask about bleeding history, and make an explicit decision about continuation or discontinuation with full patient involvement. Document the decision. The patient on warfarin for 10 years who is actively dying does not benefit from stroke prevention — they benefit from removal of a bleeding risk and one fewer medication.[22]
2
Digoxin toxicity is a reversible cause of nausea and anorexia frequently attributed to disease progression
At enrollment, check a digoxin level and a creatinine. A digoxin level above 1.5 ng/mL in a patient with declining renal function is toxicity until proven otherwise. Symptoms (nausea, anorexia, visual disturbances, confusion) improve within 1–2 days of dose reduction. This is one of the highest-impact diagnose-and-treat interventions in the AF hospice population. Do not attribute nausea to "the disease" without checking this level first.[15]
3
Tachycardia-induced cardiomyopathy is reversible if caught
If a patient has reduced EF and permanent AF with a ventricular rate running 100–130 bpm, the cardiomyopathy may be primarily tachycardia-induced rather than structural. Aggressive rate control to <80 bpm for 3–6 months can restore meaningful EF. Ask whether rate-related EF reduction has been evaluated and whether adequate rate control trials have been completed. This is one of the few reversible causes of heart failure in hospice — identifying it changes the prognosis.[21]
4
Lenient rate control reduces medication burden in appropriate patients
Many elderly AF patients with preserved EF are on unnecessary doses of rate control medications pursuing a <80 bpm target when <110 bpm would provide equivalent outcomes with lower medication burden and fewer side effects. The RACE II trial demonstrated non-inferiority. Review rate control targets at enrollment — you may be able to reduce 2–3 medications significantly by accepting a lenient rate target in patients with preserved EF.[20]
5
Switch warfarin to apixaban at enrollment when eligible
If the patient is on warfarin for non-valvular AF (not mechanical valve, not mitral stenosis), switching to apixaban eliminates INR monitoring, reduces intracranial hemorrhage risk, and reduces caregiver burden. This is a clinical gift to the patient and family. Check: CrCl >25, no mechanical valve, no mitral stenosis. The transition is simple: stop warfarin, start apixaban when INR <2.0. One intervention, massive quality-of-life impact.[19]
6
Hypokalemia and hypomagnesemia make AF worse and rate control harder
Almost every AF hospice patient is on a diuretic. Diuretics deplete potassium and magnesium. Low K+ and Mg2+ directly worsen AF burden and reduce rate control medication efficacy. Check both at enrollment and replace aggressively. KCl 20–40 mEq daily and magnesium glycinate 200–400 mg daily are standard. Correcting electrolytes before escalating rate control medications saves medication burden.[26]
7
Racial disparities in AF anticoagulation are documented and significant
Black patients with AF are less likely to be prescribed anticoagulation, less likely to receive DOACs over warfarin, and more likely to have subtherapeutic INR if on warfarin — despite having higher stroke risk. The ORBIT-AF and other registries demonstrate persistent disparities. At every enrollment, ensure the anticoagulation decision is made on clinical criteria alone. If a patient was not offered appropriate anticoagulation, address it.[34]
8
Amiodarone discontinuation requires careful management
Amiodarone has a half-life of 40–55 days. Stopping it abruptly is generally safe from a cardiac standpoint but can cause thyroid dysfunction (particularly hyperthyroidism from iodine load release) weeks after discontinuation. If you stop amiodarone, monitor for symptoms of hyperthyroidism (tremor, weight loss, palpitations, anxiety) for 4–8 weeks afterward. Also inform the team that the AF rate may gradually increase over weeks as amiodarone effects wash out — adjust rate control accordingly.[16]
"The number of times I've checked a digoxin level on a nauseated elderly AF patient and found it at 2.3 with a creatinine of 2.1 — and nobody had checked either in months. You reduce the dose, the nausea clears in two days, the family thinks you're a genius. You're not a genius. You just checked the level."
— Waldo, NP
Psychosocial & Spiritual Care
Existential distress, palpitation anxiety, rhythm control grief, and the anticoagulation conversation. The symptom burden you cannot see on a vitals sheet.
The AF patient at end of life carries a specific set of psychological burdens that are distinct from other cardiac diagnoses. The irregular heartbeat is a constant, palpable reminder of disease. The years of rhythm control efforts — cardioversions, ablations, medication trials — represent a history of medical investment and hope. And the anticoagulant has become, for many patients, a ritual of safety that represents the medical system's attention to their stroke risk. Each of these creates psychosocial needs that require explicit attention.[35]
AF-Specific Psychosocial Themes
Palpitation Anxiety & Rhythm Hypervigilance
Grade BThe patient who has had AF for years often develops a constant background awareness of their heart rhythm. Every irregular beat triggers anxiety. This hypervigilance amplifies the symptom burden beyond what the arrhythmia causes physiologically.[36]
- Address the anxiety dimension explicitly: Lorazepam 0.5 mg PRN for acute palpitation-related panic
- Mindfulness and body scan techniques: Redirect attention from cardiac monitoring to whole-body awareness
- Direct acknowledgment: "The fear of the arrhythmia can be more disabling than the arrhythmia itself. Let's address the fear."
- Refer to social work for cognitive-behavioral strategies; chaplaincy if existential dimension is predominant
Rhythm Control Grief
Grade CFor patients who spent years pursuing sinus rhythm through cardioversions, antiarrhythmic drugs, and ablation procedures, the transition to permanent AF is experienced as a medical failure.
- It is not a failure — it is a realistic acceptance of the disease trajectory — but the patient who had their third ablation six months ago and is still in AF carries a specific grief
- Name it: "You worked incredibly hard to restore your normal rhythm. That work was not wasted — it gave you years of better function. The heart has reached a point where rhythm restoration is no longer possible, but comfort and quality of life are absolutely within reach."
- Distinguish grief from depression — both deserve attention; grief may need acknowledgment more than pharmacotherapy
Anticoagulation & Existential Themes
Anticoagulation as the Anchor of Safety
- For many patients, the anticoagulant (especially warfarin with its regular INR monitoring) has become a ritual of safety over years or decades
- It represents the medical system's attention, the clinician's vigilance, the measurable proof that something is being done
- The decision to stop it can feel like abandonment — address this explicitly
- Frame as comfort decision: "Stopping the blood thinner is not stopping caring for you — it is choosing to remove a bleeding risk now that your situation has changed"
- For warfarin patients: the loss of regular INR monitoring visits may also mean loss of regular clinical contact — ensure the hospice visit schedule fills this gap
Cumulative Chronic Multimorbidity Burden
- Most AF hospice patients have AF as one of several serious diagnoses — CHF, cardiomyopathy, COPD, diabetes, CKD
- The patient has been managing multiple simultaneous serious conditions for years — a different kind of exhaustion than a single progressive diagnosis
- Acknowledge the cumulative burden: "You have been fighting on multiple fronts for a long time. It is reasonable to feel exhausted by the sheer volume of what you've been managing."
- Medication fatigue is real — the pill burden itself becomes a source of suffering; deprescribing is a psychological intervention as much as a medical one
Clinical Pearl
"The AF patient who says 'I'm fine' while clutching their chest every time they feel a skip is not fine. They have adapted to a level of cardiac hypervigilance that is exhausting them psychologically. Naming this — 'You've been on guard duty for your own heartbeat for years, and you're allowed to stand down' — is sometimes the most therapeutic thing you can say at the bedside."
Goals-of-Care Communication — AF Specific
Key AF Conversations
- "What has living with this irregular heartbeat been like for you?" — opens the door to both physical and emotional burden
- "If you had a serious bleed from the blood thinner, what would you want us to do?" — advance planning for anticoagulation complications
- "The blood thinner has been protecting you from stroke. Now that things are changing, let's talk about whether it's still the right choice." — anticoagulation deprescribing framing
- "What matters most to you right now — preventing a possible stroke, or reducing the number of pills and risks?" — values clarification
Spiritual Assessment in AF
- Use the FICA framework: Faith/beliefs, Importance, Community, Address
- The heart carries symbolic weight across all cultures — "a broken heart," "the heart of the matter" — the AF patient may experience their arrhythmia as metaphorically meaningful
- Ask: "What gives you strength during this time?" — opens spiritual conversation without assuming any tradition
- Involve chaplaincy at enrollment — spiritual care is a clinical discipline, not an optional add-on
"I had a patient who'd been on warfarin for fifteen years. Every two weeks, she went to the anticoagulation clinic. It was her routine — her connection to the system that was keeping her alive. When we stopped the warfarin because she was actively dying, her daughter cried. Not because she didn't understand. Because that clinic visit was the last thing that felt like fighting. You have to name that. You have to say: 'We are still fighting. We're just using different tools now.'"
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has a condition called atrial fibrillation — an irregular heart rhythm that affects millions of people. It is being managed with medications that control the heart rate and, in some cases, a blood-thinning medication that helps prevent stroke. The hospice team is here to make sure these medications are working well, that side effects are minimized, and that your loved one is as comfortable as possible. Here is what you may notice and how you can help.
Su ser querido tiene fibrilación auricular — un ritmo cardíaco irregular. El equipo de hospicio se asegura de que los medicamentos funcionen bien y de que esté lo más cómodo posible.
What You May See
- Irregular heartbeat: The heart is beating out of its normal rhythm. This is the AF — it may be noticeable as fluttering, racing, or pounding sensations. It is managed with medications and is expected.
- Fatigue and reduced activity: The irregular rhythm reduces the heart's pumping efficiency. Fatigue after minimal activity is expected. Rest is appropriate and should not be fought.
- Shortness of breath: Particularly if the heart rate is too fast or if there is underlying heart failure. The nurse will assess the rate and adjust medications. A fan directed at the face can help.
- Nausea and loss of appetite: If these symptoms appear, tell the nurse immediately — this can sometimes be caused by a medication level that needs adjustment. Do not assume it is just the disease.
- Swelling in legs and ankles: The heart is not pumping efficiently. The diuretic medication manages this. Follow daily weight monitoring as instructed by the nurse.
- Potential changes to blood thinner medication: Your nurse may discuss whether to continue, change, or stop the blood thinner based on current health goals. This is an important conversation that the nurse will guide carefully.
How You Can Help
- Report palpitation changes: If palpitations are new or suddenly worse — especially with dizziness, near-fainting, or sudden worsening of breathing — call the nurse. These may signal rate control needing adjustment.
- Watch for bleeding signs: Unusual bruising, blood in urine or stool, prolonged bleeding from minor cuts. Call the nurse same day for any significant bleeding. If on warfarin, keep dietary vitamin K intake consistent (leafy greens at steady levels — dramatic changes affect the blood thinner).
- Give medications at consistent times: Rate control medications work best at regular dosing times. A missed dose can cause rapid heart rate and breathlessness within hours.
- Know the anticoagulation decision: Ask the nurse whether the blood thinner is being continued and why. This is not a question you should be afraid to ask — it is one of the most important treatment decisions in this condition.
- Keep a fan nearby: A small fan directed at the face reduces the feeling of breathlessness — this is supported by research and works remarkably well.
- Take care of yourself: Caregiving for someone with a chronic heart condition is exhausting — especially when the medication list is long and the monitoring feels constant. You are allowed to feel tired. Call the hospice team when you need support.
📞 Call the nurse immediately if you see:
Sudden severe shortness of breath that is worse than usual, especially at rest. New chest pain or pressure. Fainting or near-fainting (sudden dizziness, going pale, almost passing out). Heart rate that feels extremely rapid and sustained (pounding for more than 30 minutes without relief). Any significant bleeding — blood in urine, black/tarry stool, vomiting blood, large unexplained bruises, or bleeding that won't stop with pressure. Sudden confusion or difficulty speaking or moving one side of the body (signs of stroke — call 911 if consistent with patient's goals of care). Sudden severe swelling in one leg (possible blood clot).
🙏 Your presence matters more than you know. Research consistently shows that patients with engaged family support experience better symptom control, less anxiety, and greater comfort. You are part of the care team — not a bystander. The irregular heartbeat may be unsettling to watch, but know that the medications are managing it, the nurse is monitoring it, and your loved one feels your presence even when they cannot express it.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Check the digoxin level at the first visit. Always. An elderly patient on digoxin with declining renal function who is nauseated and has lost their appetite has digoxin toxicity until proven otherwise. The level comes back at 2.1, you reduce the dose, the nausea resolves within 48 hours, and the family stops thinking their loved one is dying of cancer when they're actually dying of a medication side effect. This single lab value makes more clinical difference than almost anything else you will do at that visit. It takes five minutes to order. Do it.
- 02Make the anticoagulation decision explicit at enrollment. Do not inherit the warfarin or DOAC without asking: is this still serving the patient? Calculate CHA₂DS₂-VASc and HAS-BLED, estimate life expectancy, ask about bleeding history, ask what the patient wants if they have a serious bleed. Then document the decision. The cardiologist prescribed it, the PCP continued it, the hospital renewed it — and nobody along the way asked whether the risk-benefit had shifted. You are the person who asks. You are the person who documents. This is your job.
- 03Switch from warfarin to apixaban if the patient is not in a warfarin-only indication. Mechanical valve or mitral stenosis? Warfarin stays. Everything else? Switch to apixaban. It eliminates INR monitoring — which means no more anticoagulation clinic visits, no more finger sticks, no more dose adjustments, no more dietary vitamin K anxiety for the family. It has the lowest intracranial hemorrhage rate of any anticoagulant. The transition takes one conversation and one prescription. It is a clinical gift to the patient and the caregiver. Do it at the first visit.
- 04Identify tachycardia-induced cardiomyopathy before assuming the reduced EF is structural and terminal. A patient with AF running at 115 bpm whose ejection fraction dropped after the AF started may have recoverable cardiomyopathy — not end-stage heart failure. Aggressive rate control to under 80 bpm for 3–6 months, or AV node ablation with pacemaker, may restore meaningful cardiac function. I have seen patients reclassified from hospice-appropriate to functional independence because someone finally controlled the rate. This is one of the rare reversible causes of heart failure in hospice and it is frequently missed because nobody asked when the EF dropped relative to when the AF started.
- 05Lenient rate control is evidence-based for most permanent AF patients with preserved EF. The RACE II trial proved it. You do not need to chase a heart rate under 80 in an elderly patient with preserved EF and no tachycardia-induced cardiomyopathy. A rate of 95 at rest with no symptoms is perfectly acceptable. Accepting lenient rate control means you can use lower doses of beta-blockers or CCBs, which means less hypotension, less fatigue, less bradycardia, fewer falls. Review the rate control target at enrollment. In many patients, you will find you can reduce two or three medication doses by simply adjusting the target from 80 to 110.
- 06The amiodarone conversation needs to happen at enrollment or it will never happen. Amiodarone requires thyroid function tests, liver function tests, chest X-rays, and ophthalmology exams. At what point is that monitoring burden incompatible with comfort care? That point is usually at hospice enrollment. If the patient has been on amiodarone for years and is now on hospice for end-stage CHF, ask: is the amiodarone still providing meaningful benefit, and is the monitoring still feasible? The answer is usually no to both. Plan the discontinuation carefully — the drug has a 40–55 day half-life — and watch for thyroid dysfunction for 4–8 weeks afterward.
- 07Stop talking about the irregular heartbeat like it's the enemy. The patient has been told for years that their heart rhythm is abnormal, disordered, chaotic. Every word the medical system has used is frightening. When you're sitting with an AF patient in hospice, reframe it: "Your heart has found its own rhythm. It's not the textbook rhythm, but it has kept you alive and it is being managed. We are not trying to fix the rhythm anymore — we are making sure you are comfortable with the rhythm your heart has chosen." Language matters. The way you describe the arrhythmia affects the patient's anxiety about it.
- 08Black patients with AF are underanticoagulated at every level of the healthcare system. The data is clear — ORBIT-AF, ACTION-AF, and multiple registries show that Black patients are less likely to receive DOACs, more likely to stay on warfarin with subtherapeutic INR, and more likely to have AF diagnosed later. At the hospice enrollment visit, the anticoagulation decision should be made on clinical criteria alone — CHA₂DS₂-VASc, HAS-BLED, life expectancy, patient goals. If you find a patient who should have been on a DOAC and wasn't, correct it. If you find a patient who should have been offered anticoagulation and wasn't, document why and address it. Equity is not theoretical. It is clinical.
- 09The family of the AF patient has been managing a complex medication regimen for years and they are exhausted. They have been counting pills, tracking INRs, watching dietary vitamin K, managing multiple cardiologist and PCP appointments, and living with the constant background anxiety that a stroke could happen at any moment. When you walk in and say "we're going to simplify this," the relief is palpable. Deprescribing in AF is not just a medical intervention — it is a psychological one. Every medication you can safely remove is one fewer thing the caregiver has to worry about. Honor that. Tell them: "You have been doing a remarkable job managing all of this. Let us help carry some of that weight now."
- 10At the end, the heart rhythm doesn't matter. The rate control doesn't matter. The anticoagulation doesn't matter. What matters is that someone is present, that pain is controlled, that breathing is comfortable, and that the patient knows they are not alone. I've sat with AF patients in their final hours whose hearts were racing at 140 with an irregular rhythm that would make a cardiologist reach for the code cart — and the patient was peaceful because we had morphine on board, the family was at the bedside, and the room was quiet. The arrhythmia is not the patient. The patient is the person in the bed who needs you to be present. Be present. That's the whole job at the end.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. JAMA. 2001;285(18):2370-2375.
2
Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-1046.
3
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
4
Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6A):2D-8D.
5
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140(2):e125-e151.
6
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation (AFFIRM). N Engl J Med. 2002;347(23):1825-1833.
7
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373-498.
8
Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001;76(5):467-475.
9
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093-1100.
10
Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors. Circulation. 2011;123(14):1501-1508.
11
Voskoboinik A, Prabhu S, Ling LH, et al. Alcohol and atrial fibrillation: a sobering review. J Am Coll Cardiol. 2016;68(23):2567-2576.
12
Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304(20):2263-2269.
13
Van Gelder IC, Rienstra M, Crijns HJ, et al. Rate control in atrial fibrillation. Lancet. 2016;388(10046):818-828.
14
Kotecha D, Bunce C, Gill SK, et al. Rate control therapy for atrial fibrillation: systematic review and network meta-analysis. BMJ. 2024;384:e075325.
15
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533.
16
Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm. 2007;4(9):1250-1259.
17
Stiell IG, Macle L, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):38-46.
18
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure (CASTLE-AF). N Engl J Med. 2018;378(5):417-427.
19
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365(11):981-992.
20
Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation (RACE II). N Engl J Med. 2010;362(15):1363-1373.
21
Gopinathannair R, Etheridge SP, Marchlinski FE, et al. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66(15):1714-1728.
22
Hartman D, Lussier M, Bhatt DL, et al. Discontinuation of anticoagulation in patients with atrial fibrillation near the end of life. J Pain Symptom Manage. 2020;59(2):215-221.
23
Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676.
24
Lakkireddy D, Atkins D, Pillarisetti J, et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation. J Am Coll Cardiol. 2013;61(11):1177-1182.
25
Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101(10):1138-1144.
26
Salaminia S, Sayehmiri F, Angha P, et al. Evaluating the effect of magnesium supplementation and cardiac arrhythmias after acute myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2018;18(1):129.
27
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure (Q-SYMBIO). JACC Heart Fail. 2014;2(6):641-649.
28
Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk (STRENGTH). JAMA. 2020;324(22):2268-2280.
29
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106.
30
Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83(1):52-60.
31
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). N Engl J Med. 2011;365(10):883-891.
32
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139-1151.
33
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523-528.
34
Essien UR, Holmes DN, Jackson LR II, et al. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018;3(12):1174-1182.
35
Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448.e1-448.e19.
36
McCabe PJ, Schumacher K, Barnason SA. Living with atrial fibrillation: a qualitative study. J Cardiovasc Nurs. 2011;26(4):336-344.
37
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48). N Engl J Med. 2013;369(22):2093-2104.
38
Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation (CABANA). JAMA. 2019;321(13):1261-1274.
39
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
40
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272.
41
Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation (ELDERCARE-AF). N Engl J Med. 2020;383(18):1735-1745.
42
Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the ORBIT-AF registry. Circ Arrhythm Electrophysiol. 2013;6(2):258-264.
43
Todd OM, Wilkinson C, Parker SG, et al. Management of atrial fibrillation in older adults: a review. JAMA. 2023;330(1):74-84.
44
Holmes DN, Piccini JP, Allen LA, et al. Defining clinically important difference in the atrial fibrillation effect on quality of life (AFEQT) score. Circ Cardiovasc Qual Outcomes. 2019;12(5):e005358.
45
LeBlanc TW, McNeil MJ, Kamal AH, et al. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16(7):e333-e341.
46
Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation: focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209-218.
47
Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377(5):431-441.
48
Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-1335.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.